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For older populations, most of whom are women, pre-
venting illnesses and deaths through the use of vaccines is
a leading public health challenge. Our understanding about
how age and sex affect the immune system is limited, and
basic and translational research aimed at improving vac-
cines and immune responses of older persons is needed.
In the meantime, fully implementing current vaccine recom-
mendations, particularly those for influenza and pneumo-
coccal vaccines, can save thousands of lives and prevent
illnesses in persons >50 years of age. 
I
n the United States, the elderly are more likely to die of
a vaccine-preventable disease. Adult deaths from
influenza (≈36,000/y) (1,2), invasive pneumococcal dis-
ease (≈9,000/y) (3), and hepatitis B (≈5,000/y) (4) exceed
vaccine-preventable deaths among children (≈50/y) by a
ratio of ≈1,000:1. For each of these diseases, case-fatality
rates rise with increasing age. This disparity can be
addressed through adult vaccination programs, which are
cost-effective and life-saving. Women constitute most of
the adult U.S. population >50 years of age (60% of those
75 years of age and 70% of those 85 years of age).
The immune system does not function as well with
advancing age (5). For example, T-cell functions diminish
with age, as evidenced by the increased prevalence of
anergy to mycobacterial and fungal skin-test antigens and
the increased frequency and severity of herpes zoster
infection with age. B-cell function diminishes, as seen with
the lessened humoral response (immunoglobulin [Ig] M,
IgG, and IgA) to certain vaccines (e.g., hepatitis B, influen-
za, pneumococcal vaccine), and the protective efficacy of
these vaccines also decreases as recipients age (6,7).
Differences in Immunologic Response by Sex
Very little is known about differences in the immuno-
logic response to vaccines or their protective efficacy,
according to sex and age. Higher antibody responses have
been noted in women after hepatitis B vaccination (8,9).
Trials are being completed to evaluate the effect of high
dose varicella vaccine in reducing the high rates of herpes
zoster and postherpetic neuralgia (10,11) in elderly. Some
studies suggest that these problems preferentially involve
older women. However, none of the differences reported
between sexes are of a magnitude that affects any of the
current vaccine recommendations.
The 2003–2004 Recommended Adult Immunization
Schedule by Age Group, United States (12) (available
from http://www.cdc.gov/nip/recs/adult-schedule.htm)
covers the vaccines most commonly used for specific age
brackets (Figure). We discuss the vaccines universally rec-
ommended for adults >50 years of age and selected vac-
cines for international travelers. Vaccine recommendations
for special medical conditions (e.g., asplenia, pregnancy,
diabetes, immunodeficiency, HIV infection, hepatitis
exposures) may be found elsewhere (12).
Universal Vaccines for Persons > >50 Years of Age
Influenza
In an average year in the United States, influenza caus-
es  ≈36,000 deaths, 114,000 hospitalizations, 25 million
physician visits, and an additional 30–60 million milder
infections (1). Death and severity of illness are correlated
with increasing age and underlying conditions. Persons at
high risk for influenza complications include persons >65
years of age, residents of chronic-care facilities, and per-
sons with chronic medical conditions, such as pulmonary,
metabolic, or cardiovascular disorders; renal dysfunction;
immunocompromised conditions; and splenic absence or
dysfunction. Because ≈30% of the U.S. population 50–64
years of age have one or more conditions that warrant
influenza vaccination (1) and because age-based recom-
mendations are easier to implement, 50 years of age has
now been established as the time for beginning the univer-
sal annual influenza vaccination (13).
The only influenza vaccine currently licensed for per-
sons >50 years of age is the killed trivalent influenza vac-
cine (TIV), which is annually constituted to contain the
two type A strains and one type B strain thought most
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usually becomes available in late September and should be
administered annually, ideally from September to
November. If the circulating and vaccine strains are well
matched, 70%–90% of healthy recipients <65 years of age
will be protected against influenza. In elderly and
immunocompromised recipients, disease prevention rates
are lower because of decreased immune response, but the
vaccine is still effective in reducing the severity of illness.
In elderly persons living in nursing homes, influenza vac-
cine can be 50%–60% effective in preventing hospitaliza-
tion and pneumonia and 80% effective in preventing
influenza-related deaths (14–16). Substantial reductions of
cardiac events and cerebrovascular disease, as well as
pneumonia, among influenza vaccine recipients >65 years
of age have been reported from a large study in Minnesota
(17). If this finding is confirmed, it would be an added ben-
efit of influenza vaccination in elderly populations.
Current rates of influenza vaccination by population
group are shown in the Table (1). Although the rates in
nursing home residents (83%) are approaching the goal
(90%) set by the Healthy People 2010 initiative, the over-
all rates for the elderly have been stalled at 65% to 67% for
the past 3 years and less that one third of persons at high
risk in younger age groups have been vaccinated. Fully
implementing the current influenza vaccine recommenda-
tions would prevent many illnesses and deaths annually,
particularly in the elderly, and is a potentially cost-saving
public health challenge. 
Influenza vaccination of healthcare workers has been a
long-standing recommendation for prevention of nosoco-
mial spread of influenza, especially to persons at high risk.
Vaccinating healthcare workers in nursing homes has been
reported to reduce disease among the residents (18,19);
therefore, the overall rate (36%) of vaccination among
healthcare workers needs to be increased. 
A trivalent, live, attenuated, cold-adapted influenza
vaccine (LAIV-T) has been licensed for use in persons
5–49 years of age (1,20). The vaccine is administered by
intranasal spray and induces local mucosal immunity as
well as systemic immunity. This vaccine appears to pro-
vide protection similar to the TIV vaccine and may be
superior in years when the vaccine strains do not closely
match the circulating virus. LAIV-T requires special cold
storage and is more expensive than TIV. At the time of
licensure, not enough data regarding its use in elderly per-
sons were presented, and approval for adult use was grant-
ed only up to 50 years of age. Studies in older adults are in
progress.
The addition of neuraminidase inhibitors (oseltamivir
and zanamivir) to the arsenal of chemoprophylactic and
therapeutic drugs for influenza poses further options, espe-
cially for the elderly, who generally respond less well to
vaccines. While previously available drugs, amantadine
and rimantadine, have similar efficacy against influenza A
and are less expensive, the newer drugs have fewer serious
side effects and provide protection against influenza B as
well. Data are limited and inconclusive concerning the
effectiveness of these drugs for preventing or treating seri-
ous complications of influenza.
Questions remain about how best to prevent or modify
influenza in the elderly. Should a vaccine with increased
antigen dosage or different adjuvants be developed in the
hope of improving the antibody levels in older persons?
Would a vaccination schedule of twice per season, e.g.,
October/November and January/February, give more sus-
tained protection to the elderly? Because the immunologic
response diminishes with age, should those >80 years of
age also receive antiviral chemoprophylaxis during influen-
za outbreaks? Should antiinfluenza drugs be added to the
empiric initial treatment of patients hospitalized for com-
munity-acquired pneumonia during the influenza season?
Pneumococcal Disease
The incidence of and deaths from invasive pneumococ-
cal disease rise sharply among adults after 50 years of age
(3). Invasive pneumococcal diseases, mainly bacteremia
and meningitis, cause ≈9,000 deaths per year in the United
States, with case-fatality rates that exceed 50% in the eld-
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Figure. Recommended Adult Immunization Schedule, United
States, 2003-2004 (12). This schedule indicates the recommend-
ed age groups for routine administration of currently licensed
vaccines for persons >19 years of age. See http://www.
cdc.gov/nip/recs/adult-schedule.htm for complete documentation
of the numbered footnotes.erly. Estimates of pneumococcal pneumonia vary from
500,000 cases per year (3,21) to 106,000–175,000 cases
per year (22), with case-fatality rates of 5% to 7% among
the hospitalized elderly. Pneumococcal disease rates are
substantially elevated in certain minority populations,
including African-Americans, Alaska natives, and Native
Americans.
The pneumococcal polysaccharide vaccine (PPV),
which is available for use in adults, consists of purified
capsular polysaccharide from the 23 serotypes of pneumo-
coccus, which account for approximately 85%–90% of
cases of invasive pneumococcal disease. Overall, this vac-
cine is ≈60% effective in preventing invasive pneumococ-
cal disease caused by serotypes included in the vaccine but
is less effective in the elderly (23). The vaccine has not
demonstrated consistent benefit in preventing pneumococ-
cal pneumonia (23–25).
The PPV vaccine is recommended for all adults >65
years (12) and for younger adults with chronic medical
conditions, including diabetes, heart disease, chronic pul-
monary disease (excluding asthma), chronic liver disease
(including alcoholism), renal disease, asplenia or splenic
dysfunction, HIV infection, and immunodeficiency states
(12).
Recent surveys indicate that 66% of persons >65 years
of age have received one or more PPV vaccinations (26).
However, vaccination rates are lower for African-
Americans and other minority groups and for younger
adults with medical conditions that place them at higher
risk for invasive pneumococcal disease. This situation
indicates a major preventive medicine opportunity through
full implementation of the current recommendations for
PPV use. The antibody levels and protective efficacy pro-
vided by PPV vaccination gradually wane. Because PPV
stimulates B-cells but does not induce T-cell memory,
revaccination does not produce an anamnestic response.
However, it usually elicits a rise in antibody that approxi-
mates the response to the initial vaccination (27). 
In the absence of studies of the protective efficacy after
revaccination and insufficient safety studies by age, advi-
sory committees have been reluctant to issue firm direc-
tives. To date, routine revaccination is not recommended
for immunocompetent persons who were first vaccinated
>65 years of age. However, for persons who were first vac-
cinated before 65 years of age for reason of increased risk,
a single revaccination is recommended (12). In the absence
of data, some practicing physicians, given the overall good
safety profile and low cost of PPV, have chosen to revac-
cinate elderly patients at 5- to 10-year intervals as a pru-
dent response to the increasing rates of pneumococcal dis-
ease and deaths with age.
Additional questions about PPV recommendations
exist. Should the vaccine indications be broadened to
include those who smoke cigarettes, now shown to be a
major risk factor for invasive pneumococcal disease, (28)
and minority groups who have 2–10 times more invasive
pneumococcal disease than that of the general population?
Should the age for universal vaccination of adults be low-
ered to 50 years of age (29,30) on the basis of the observa-
tions that ≈30% of adults 50–64 years of age have risk fac-
tors for which PPV is indicated (13,29)? Approximately
18% of the U.S population is made up of minority groups
who have high rates of pneumococcal disease, and approx-
imately one quarter of Americans 50–64 years of age
smoke cigarettes. An added advantage to lowering the age
of universal PPV vaccination to 50 years of age would be
the “harmonization” of the adult pneumococcal vaccina-
tion schedule with the recommendations for influenza vac-
cine (30), thereby simplifying the system and hopefully
improving the poor implementation rates of condition-
based recommendations. 
Finally, the development of a seven-valent pneumococ-
cal conjugate vaccine for infants and young children has
been a major advance that provides >90% protection
against invasive pneumococcal disease in young children.
Since young children are an important reservoir of pneumo-
coccal carriage and spread it to others, vaccinating young
children has provided a beneficial herd immunity that
results in substantial reductions of pneumococcal disease in
other children and adults (31). Developing a pneumococcal
conjugate vaccine suitable for adults has been difficult.
Tetanus-Diphtheria (Td) Toxoid Boosters
Tetanus toxoid and diphtheria toxoid are excellent
immunogens. The primary vaccination series in childhood
provides high-level protection and induces long-lasting
immunologic memory, as evidenced by an anamnestic
antibody response to Td after intervals of >30 years. High
levels of primary vaccination and appropriate wound care
(including Td boosters) are the cornerstones of tetanus pre-
vention in the United States. The current recommendation
that all adults in the United States receive Td boosters
every 10 years has been poorly implemented, as evidenced
by serosurveys showing that most adults >50 years of age
lack protective levels of antibodies to either tetanus toxoid,
diphtheria toxoid, or both (32). Despite this high level of
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(0–3 cases/y) are rare diseases and almost always occur in
persons who never completed the full schedule of child-
hood vaccinations. Cost and benefit studies favor a policy
of a single mid-life Td booster for persons who have com-
pleted the full pediatric series (33), and several advisory
groups have recommended a booster at 50 years of age as
an alternative to the current standard of decennial boosters
(12,34). Consideration of reducing the frequency of Td
boosters will be complicated by the proposed addition of
the acellular pertussis vaccine to the adult Td formulation,
as it is more costly and induces a shorter duration of anti-
body response than Td.
Vaccines for Travelers >50 Years of Age 
The increasing participation of older people in interna-
tional travel raises an additional set of vaccination issues.
Influenza and pneumococcal vaccinations should not be
overlooked for travelers, especially during the different
winter season in the Southern Hemisphere. Similarly, the
crowding of people from many parts of the world on cruise
ships or other international gatherings, is a setting in which
influenza and other seasonal viruses may occur out of sea-
son. Hepatitis A vaccine is indicated for all travelers to
areas of the world where sanitation or water safety are in
question. Although approximately one half the U.S. popu-
lation >50 years of age has serologic evidence of immuni-
ty to hepatitis A because of previous hepatitis A exposure,
the pragmatic policy is to give hepatitis A vaccine rather
than to serologically screen and vaccinate only the
immunosusceptible persons. The vaccine is safe and high-
ly protective when given preexposure and may have bene-
fit when administered early in the postexposure setting.
Two doses spaced >6 months apart are recommended,
although serologic and epidemiologic data suggest that
one dose may provide long-term protection. No data are
available to indicate the duration of protection in the elder-
ly. For persons who also require hepatitis B vaccination, a
combined hepatitis A- hepatitis B vaccine (Twinrix) pro-
vides a convenient three-dose method of vaccination.
Hepatitis B vaccine is indicated for persons planning long-
term travel (generally >6 weeks) to areas of high hepatitis
B prevalence or who anticipate parenteral exposure (dental
procedures, needle exposure, blood products) or sexual
exposure to hepatitis B virus. The standard three-dose
schedule is 0, 1, and 6 months, although an accelerated
schedule of 0, 1, and 4 weeks offers good short-term pro-
tection but requires a fourth dose at 1 year. The duration of
protection is not well defined but appears to exceed the
duration of the antibody response; therefore, no firm rec-
ommendation exists regarding booster doses. However, the
immune response to hepatitis B vaccine diminishes
sharply with age and for older persons. For older persons
with continual or repeated exposures to hepatitis B, meas-
uring antibody levels and considering boosters for those
with low levels are advisable. Yellow fever vaccine, a live,
attenuated viral vaccine, is indicated for travelers to dis-
ease-endemic areas of South America and sub-Saharan
Africa, and several countries require proof of vaccination
as a condition of entry. Cases of yellow fever among U.S.
travelers have been few but have increased in the last
decade, and some deaths have occurred. On the other hand,
recent reports have described the rare occurrence of a sys-
temic illness mimicking yellow fever after yellow fever
vaccine administration to elderly persons (35). Therefore,
the vaccine should not be administered to persons (espe-
cially the elderly) who are not traveling to yellow
fever–endemic areas. Recommendations for the other trav-
el related vaccines (meningococcal, typhoid fever, polio,
rabies, and Japanese encephalitis) are the same for all adult
age groups and are fully described in Health Information
for International Travelers (36).
Future Developments 
Because increasing age is associated with increasing
rates of herpes zoster and post-herpetic neuralgia, studies
are under way to evaluate the administration of high-dose
varicella vaccine to persons >60 years of age in an effort to
boost antivaricella antibodies and reduce the late compli-
cations of varicella. Several promising vaccines important
to women are in development to prevent cervical cancer
(human papillomavirus vaccine), sexually transmitted dis-
eases, and transmission of pathogens (e.g., group B strep-
tococcus, cytomegalovirus) from pregnant women to their
newborns, but these vaccines are intended for younger
populations and will not be important vaccines for persons
>50 years of age. The generic problems of lessened vac-
cine response and efficacy with advanced age call for
increased research regarding the immune response in the
elderly. Approaches that appear promising include devel-
oping age- and sex-specific adjuvants, considering differ-
ent antigen doses and vaccination schedules that offer the
possibility of improving the immunologic response, and
vaccines to boost T-cell and phagocytic host defenses.
Advances in genetics will facilitate the identification of
subpopulations with unique vaccine responses. Also, the
ability to genetically engineer vaccines with higher antigen
concentrations and the capacity to combine a variety of
antigens offer the promise of broader protection with sim-
plified vaccine schedules. 
Conclusion
Preventing illnesses and deaths in older populations
from diseases that are preventable through vaccines is a
leading public health challenge. Our understanding of the
effects of age and sex on the immune system is limited.
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ly for influenza and pneumococcal vaccines, offers the
immediate prospect of saving thousands of lives and
reducing major illnesses among persons >50 years of age.
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